Literature DB >> 19088940

Validation of a prognostic nomogram in patients undergoing resection for pancreatic ductal adenocarcinoma in a UK tertiary referral centre.

E J Clark1, M A Taylor, S Connor, R O'Neill, M F Brennan, O J Garden, R W Parks.   

Abstract

INTRODUCTION: Survival following resection for pancreatic ductal adenocarcinoma (PDAC) remains poor. The aim of this study was to validate a survival nomogram designed at the Memorial Sloan-Kettering Cancer Centre (MSKCC) in a UK tertiary referral centre.
METHODS: Patients who underwent resection for PDAC between 1995 and 2005 were analysed retrospectively. Standard prognostic factors and nomogram-specific data were collected. Continuous data are presented as median (inter-quartile range).
RESULTS: Sixty-three patients were analysed. The median survival was 326 (209-680) days. On univariate analysis lymph node status (node +ve 297 (194-471) days versus node -ve 367 (308-1060) days, p=0.005) and posterior margin involvement (margin +ve 210 (146-443) days versus margin -ve 355 (265-835) days, p=0.024) were predictors of a poor survival. Only lymph node positivity was significant on multivariate analysis (p=0.006). The median nomogram score was 217 (198-236). A nomogram score of 113-217 predicted a median survival of 367 (295-847) days compared to 265 (157-443) days for a score of 218-269, p=0.012.
CONCLUSION: Increasing nomogram score was associated with poorer survival. However the accuracy demonstrated by MSKCC could not be replicated in the current cohort of patients and may reflect differences in patient demographics, accuracy of pathological staging and differences in treatment regimens between the two centres.

Entities:  

Keywords:  nomogram; pancreatic adenocarcinoma; prognosis

Year:  2008        PMID: 19088940      PMCID: PMC2597327          DOI: 10.1080/13651820802356606

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  29 in total

1.  Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

Authors:  J L Cameron; D W Crist; J V Sitzmann; R H Hruban; J K Boitnott; A J Seidler; J Coleman
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

2.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

3.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

4.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  The need for standardized pathologic staging of pancreaticoduodenectomy specimens.

Authors:  C A Staley; K R Cleary; J L Abbruzzese; J E Lee; F C Ames; C J Fenoglio; D B Evans
Journal:  Pancreas       Date:  1996-05       Impact factor: 3.327

Review 6.  A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer.

Authors:  S Pedrazzoli; H G Beger; H Obertop; A Andrén-Sandberg; L Fernández-Cruz; D Henne-Bruns; J Lüttges; J P Neoptolemos
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

7.  Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma.

Authors:  E J M Nieveen van Dijkum; K F D Kuhlmann; C B Terwee; H Obertop; J C J M de Haes; D J Gouma
Journal:  Br J Surg       Date:  2005-04       Impact factor: 6.939

8.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

9.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.

Authors:  Cristina R Ferrone; Michael W Kattan; James S Tomlinson; Sarah P Thayer; Murray F Brennan; Andrew L Warshaw
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

10.  Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.

Authors:  Michael W Kattan; Martin S Karpeh; Madhu Mazumdar; Murray F Brennan
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

View more
  4 in total

1.  Conditional survival in pancreatic cancer: better than expected.

Authors:  Tara S Kent; Teviah E Sachs; Norberto Sanchez; Charles M Vollmer; Mark P Callery
Journal:  HPB (Oxford)       Date:  2011-09-16       Impact factor: 3.647

2.  Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer.

Authors:  Shinuk Kim; Mee Kang; Seungyeoun Lee; Soohyun Bae; Sangjo Han; Jin-Young Jang; Taesung Park
Journal:  Biomed Eng Online       Date:  2014-12-11       Impact factor: 2.819

3.  Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.

Authors:  Lei Huang; Yesilda Balavarca; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Vesna Zadnik; Maja Primic-Žakelj; Margit Mägi; Robert Grützmann; Marc G Besselink; Petra Schrotz-King; Hermann Brenner; Lina Jansen
Journal:  BMC Med       Date:  2019-03-25       Impact factor: 8.775

4.  Preoperative Clinical and Computed Tomography (CT)-Based Nomogram to Predict Oncologic Outcomes in Patients with Pancreatic Head Cancer Resected with Curative Intent: A Retrospective Study.

Authors:  Shin Hye Hwang; Ha Yan Kim; Eun Ju Lee; Ho Kyoung Hwang; Mi-Suk Park; Myeong-Jin Kim; Woo Jung Lee; Yong Eun Chung; Chang Moo Kang
Journal:  J Clin Med       Date:  2019-10-21       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.